Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Butte, MT
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Butte, MT
Click here to add this to my saved trials
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Las Vegas, NV
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Brooklyn, NY
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Lima, OH
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Lima, OH
Click here to add this to my saved trials
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Toledo, OH
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Toledo, OH
Click here to add this to my saved trials
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Channelview, TX
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Channelview, TX
Click here to add this to my saved trials
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Houston, TX
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Phoenix, AZ
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
La Mesa, CA
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
La Mesa, CA
Click here to add this to my saved trials
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
West Palm Beach, FL
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Council Bluffs, IA
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Council Bluffs, IA
Click here to add this to my saved trials
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Hazard, KY
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Hazard, KY
Click here to add this to my saved trials
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Zachary, LA
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Zachary, LA
Click here to add this to my saved trials
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Minneapolis, MN
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Jackson, MS
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Jackson, MS
Click here to add this to my saved trials
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Lincoln, NE
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Lincoln, NE
Click here to add this to my saved trials
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Belleville, NJ
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Belleville, NJ
Click here to add this to my saved trials
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Albany, NY
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Albany, NY
Click here to add this to my saved trials
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Pittsburgh, PA
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Neptune City, NJ
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Neptune City, NJ
Click here to add this to my saved trials
Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC
Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for Patients With GATA2 Mutations
Status: Enrolling
Updated:  10/17/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC
Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for Patients With GATA2 Mutations
Status: Enrolling
Updated: 10/17/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Prevention of Catheter-Associated Urinary Tract Infection in Incontinence and Reconstructive Pelvic Surgery Patients
Prevention of Catheter-Associated Urinary Tract Infections in Patients Undergoing Incontinence and Reconstructive Pelvic Surgery: A Randomized Controlled Trial
Status: Enrolling
Updated:  10/17/2017
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Prevention of Catheter-Associated Urinary Tract Infection in Incontinence and Reconstructive Pelvic Surgery Patients
Prevention of Catheter-Associated Urinary Tract Infections in Patients Undergoing Incontinence and Reconstructive Pelvic Surgery: A Randomized Controlled Trial
Status: Enrolling
Updated: 10/17/2017
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Trial of High-Dose Rifampin in Patients With TB
Randomized Trial of High-Dose Rifampin in Patients With New, Smear-Positive TB
Status: Enrolling
Updated:  10/17/2017
University of Florida
mi
from
Gainesville, FL
Trial of High-Dose Rifampin in Patients With TB
Randomized Trial of High-Dose Rifampin in Patients With New, Smear-Positive TB
Status: Enrolling
Updated: 10/17/2017
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Trial of High-Dose Rifampin in Patients With TB
Randomized Trial of High-Dose Rifampin in Patients With New, Smear-Positive TB
Status: Enrolling
Updated:  10/17/2017
Socios En Salud Sucursal Perú
mi
from
Lima 6,
Trial of High-Dose Rifampin in Patients With TB
Randomized Trial of High-Dose Rifampin in Patients With New, Smear-Positive TB
Status: Enrolling
Updated: 10/17/2017
Socios En Salud Sucursal Perú
mi
from
Lima 6,
Click here to add this to my saved trials
Emtricitabine/Tenofovir Alafenamide as Salvage ART
Safety and Efficacy of Emtricitabine/Tenofovir Alafenamide as Part of Salvage Antiretroviral Regimens in Patients With Uncontrolled Viremia and Drug-Resistant HIV Infection
Status: Enrolling
Updated:  10/17/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Emtricitabine/Tenofovir Alafenamide as Salvage ART
Safety and Efficacy of Emtricitabine/Tenofovir Alafenamide as Part of Salvage Antiretroviral Regimens in Patients With Uncontrolled Viremia and Drug-Resistant HIV Infection
Status: Enrolling
Updated: 10/17/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Drug Penetration Into Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement Surgery
A Phase 1, Open-Label Pharmacokinetic Study to Investigate Drug Penetration in the Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement Surgery
Status: Enrolling
Updated:  10/17/2017
Mercury St Medical Group, PLLC
mi
from
Butte, MT
Drug Penetration Into Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement Surgery
A Phase 1, Open-Label Pharmacokinetic Study to Investigate Drug Penetration in the Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement Surgery
Status: Enrolling
Updated: 10/17/2017
Mercury St Medical Group, PLLC
mi
from
Butte, MT
Click here to add this to my saved trials
Drug Penetration Into Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement Surgery
A Phase 1, Open-Label Pharmacokinetic Study to Investigate Drug Penetration in the Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement Surgery
Status: Enrolling
Updated:  10/17/2017
eStudySite
mi
from
La Mesa, CA
Drug Penetration Into Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement Surgery
A Phase 1, Open-Label Pharmacokinetic Study to Investigate Drug Penetration in the Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement Surgery
Status: Enrolling
Updated: 10/17/2017
eStudySite
mi
from
La Mesa, CA
Click here to add this to my saved trials
Middle Ear Pressure Disregulation After Tympanostomy Tube Insertion
Middle Ear Pressure Disregulation After Tympanostomy Tube Insertion
Status: Enrolling
Updated:  10/17/2017
ENT Department, Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Middle Ear Pressure Disregulation After Tympanostomy Tube Insertion
Middle Ear Pressure Disregulation After Tympanostomy Tube Insertion
Status: Enrolling
Updated: 10/17/2017
ENT Department, Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection
Phase I Study of the Safety of Replication-Defective Herpes Simplex Virus-2 Vaccine, HSV529, in Adults Aged 18 to 40 Years With or Without HSV Infection
Status: Enrolling
Updated:  10/18/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection
Phase I Study of the Safety of Replication-Defective Herpes Simplex Virus-2 Vaccine, HSV529, in Adults Aged 18 to 40 Years With or Without HSV Infection
Status: Enrolling
Updated: 10/18/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection
Status: Enrolling
Updated:  10/18/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection
Status: Enrolling
Updated: 10/18/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection
Status: Enrolling
Updated:  10/18/2017
Medical Center for clinical research
mi
from
San Diego, CA
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection
Status: Enrolling
Updated: 10/18/2017
Medical Center for clinical research
mi
from
San Diego, CA
Click here to add this to my saved trials
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection
Status: Enrolling
Updated:  10/18/2017
Quest Clinical Research
mi
from
San Francisco, CA
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection
Status: Enrolling
Updated: 10/18/2017
Quest Clinical Research
mi
from
San Francisco, CA
Click here to add this to my saved trials
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection
Status: Enrolling
Updated:  10/18/2017
University of Illinois at Chicago
mi
from
Chicago, IL
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection
Status: Enrolling
Updated: 10/18/2017
University of Illinois at Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection
Status: Enrolling
Updated:  10/18/2017
Indiana University
mi
from
Indianapolis, IN
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection
Status: Enrolling
Updated: 10/18/2017
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection
Status: Enrolling
Updated:  10/18/2017
The Fenway Institute
mi
from
Boston, MA
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection
Status: Enrolling
Updated: 10/18/2017
The Fenway Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection
Status: Enrolling
Updated:  10/18/2017
Univ of North Carolina
mi
from
Chapel Hill, NC
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection
Status: Enrolling
Updated: 10/18/2017
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection
Status: Enrolling
Updated:  10/18/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection
Status: Enrolling
Updated: 10/18/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection
Status: Enrolling
Updated:  10/18/2017
NW Dermatology and Research
mi
from
Portland, OR
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection
Status: Enrolling
Updated: 10/18/2017
NW Dermatology and Research
mi
from
Portland, OR
Click here to add this to my saved trials
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection
Status: Enrolling
Updated:  10/18/2017
Magee-Womens Hospital of UPMC
mi
from
Pittsburgh, PA
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection
Status: Enrolling
Updated: 10/18/2017
Magee-Womens Hospital of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection
Status: Enrolling
Updated:  10/18/2017
Tekton Research
mi
from
Austin, TX
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection
Status: Enrolling
Updated: 10/18/2017
Tekton Research
mi
from
Austin, TX
Click here to add this to my saved trials
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection
Status: Enrolling
Updated:  10/18/2017
Center for Clinical Studies
mi
from
Houston, TX
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection
Status: Enrolling
Updated: 10/18/2017
Center for Clinical Studies
mi
from
Houston, TX
Click here to add this to my saved trials
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection
Status: Enrolling
Updated:  10/18/2017
Univ of Washington
mi
from
Seattle, WA
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection
Status: Enrolling
Updated: 10/18/2017
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Cross Linking for Treatment of Corneal Infection
A Prospective Randomized Double-masked Evaluation of Treatment Duration of the UVX System for Treating Infectious Keratitis
Status: Enrolling
Updated:  10/19/2017
Price Vision Group
mi
from
Indianapolis, IN
Cross Linking for Treatment of Corneal Infection
A Prospective Randomized Double-masked Evaluation of Treatment Duration of the UVX System for Treating Infectious Keratitis
Status: Enrolling
Updated: 10/19/2017
Price Vision Group
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides
A Multicenter, Open-label, Randomized, Phase I/II Study Evaluating the Safety and Efficacy of Low-dose (12 Gy) Total Skin Electron Beam Therapy (TSEBT) Combined With Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides (MF)
Status: Enrolling
Updated:  10/19/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides
A Multicenter, Open-label, Randomized, Phase I/II Study Evaluating the Safety and Efficacy of Low-dose (12 Gy) Total Skin Electron Beam Therapy (TSEBT) Combined With Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides (MF)
Status: Enrolling
Updated: 10/19/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides
A Multicenter, Open-label, Randomized, Phase I/II Study Evaluating the Safety and Efficacy of Low-dose (12 Gy) Total Skin Electron Beam Therapy (TSEBT) Combined With Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides (MF)
Status: Enrolling
Updated:  10/19/2017
Yale University School of Medicine
mi
from
New Haven, CT
Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides
A Multicenter, Open-label, Randomized, Phase I/II Study Evaluating the Safety and Efficacy of Low-dose (12 Gy) Total Skin Electron Beam Therapy (TSEBT) Combined With Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides (MF)
Status: Enrolling
Updated: 10/19/2017
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides
A Multicenter, Open-label, Randomized, Phase I/II Study Evaluating the Safety and Efficacy of Low-dose (12 Gy) Total Skin Electron Beam Therapy (TSEBT) Combined With Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides (MF)
Status: Enrolling
Updated:  10/19/2017
M.D. Anderson Cancer Center
mi
from
Houston, TX
Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides
A Multicenter, Open-label, Randomized, Phase I/II Study Evaluating the Safety and Efficacy of Low-dose (12 Gy) Total Skin Electron Beam Therapy (TSEBT) Combined With Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides (MF)
Status: Enrolling
Updated: 10/19/2017
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Randomized, Double-Blind, Placebo-Controlled Study: CroFab® vs Placebo for Copperhead Snake Envenomation
A Randomized, Double-Blind, Placebo-Controlled Study Comparing CroFab® vs Placebo With Rescue Treatment for Copperhead Snake Envenomation
Status: Enrolling
Updated:  10/19/2017
Augusta University
mi
from
Augusta, GA
Randomized, Double-Blind, Placebo-Controlled Study: CroFab® vs Placebo for Copperhead Snake Envenomation
A Randomized, Double-Blind, Placebo-Controlled Study Comparing CroFab® vs Placebo With Rescue Treatment for Copperhead Snake Envenomation
Status: Enrolling
Updated: 10/19/2017
Augusta University
mi
from
Augusta, GA
Click here to add this to my saved trials
Randomized, Double-Blind, Placebo-Controlled Study: CroFab® vs Placebo for Copperhead Snake Envenomation
A Randomized, Double-Blind, Placebo-Controlled Study Comparing CroFab® vs Placebo With Rescue Treatment for Copperhead Snake Envenomation
Status: Enrolling
Updated:  10/19/2017
University of Kansas Hospital
mi
from
Kansas City, KA
Randomized, Double-Blind, Placebo-Controlled Study: CroFab® vs Placebo for Copperhead Snake Envenomation
A Randomized, Double-Blind, Placebo-Controlled Study Comparing CroFab® vs Placebo With Rescue Treatment for Copperhead Snake Envenomation
Status: Enrolling
Updated: 10/19/2017
University of Kansas Hospital
mi
from
Kansas City, KA
Click here to add this to my saved trials
Randomized, Double-Blind, Placebo-Controlled Study: CroFab® vs Placebo for Copperhead Snake Envenomation
A Randomized, Double-Blind, Placebo-Controlled Study Comparing CroFab® vs Placebo With Rescue Treatment for Copperhead Snake Envenomation
Status: Enrolling
Updated:  10/19/2017
Univ of North Carolina
mi
from
Chapel Hill, NC
Randomized, Double-Blind, Placebo-Controlled Study: CroFab® vs Placebo for Copperhead Snake Envenomation
A Randomized, Double-Blind, Placebo-Controlled Study Comparing CroFab® vs Placebo With Rescue Treatment for Copperhead Snake Envenomation
Status: Enrolling
Updated: 10/19/2017
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Randomized, Double-Blind, Placebo-Controlled Study: CroFab® vs Placebo for Copperhead Snake Envenomation
A Randomized, Double-Blind, Placebo-Controlled Study Comparing CroFab® vs Placebo With Rescue Treatment for Copperhead Snake Envenomation
Status: Enrolling
Updated:  10/19/2017
Duke University
mi
from
Durham, NC
Randomized, Double-Blind, Placebo-Controlled Study: CroFab® vs Placebo for Copperhead Snake Envenomation
A Randomized, Double-Blind, Placebo-Controlled Study Comparing CroFab® vs Placebo With Rescue Treatment for Copperhead Snake Envenomation
Status: Enrolling
Updated: 10/19/2017
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials